Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Biotech
Why Lexicon is in ‘good shape to go crazy’: CEO
Lexicon CEO Michael Exton told Fierce how he set the company's development and financial pathway "on a very different trajectory."
Will Maddox
May 13, 2026 10:50am
Cytokinetics doesn't want Big Pharma help to overtake Camzyos
Nov 18, 2025 1:30pm
FDA puts Tenaya heart disease gene therapy trial on hold
Nov 10, 2025 5:16am
Braveheart, with Biogen CEO on board, rallies $185M series A
Nov 5, 2025 7:51am
Cytokinetics’ ph. 3 cardio win sends stock soaring
Sep 2, 2025 2:05pm
Rocket's gene therapy sets new efficacy bar in ph. 1 heart study
May 16, 2025 10:36am
